Latest News and Press Releases

Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's

Pasithea Therapeutics' PAS-004 abstract accepted for ASCO poster presentation: novel MEK inhibitor shows promise for NF1 and cancer therapy.

Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.

Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.

Pasithea Therapeutics unveils crystalline PAS-004, extending IP protection to 2045 for CNS disorder treatments.

Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.

Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.

Disclosure related to the annual meeting of Pasithea Therapeutics (Nasdaq: KTTA)

Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24.

Pasithea Therapeutics adjourns 2023 annual meeting of stockholders.